TO: ADULT PROVIDER	
Provider Name: Address:	
Phone:	
Fax:Email:	
Effalls.	
TO: PEDIATRIC PROVIDER	
Provider Name:	
Address:	
Phone:Fax:	
Email:	
RE:	
Name:	
Preferred pronoun(s):	
Date of Birth (MM/DD/YYYY):	
Address:Phone:	
Email [patient]:	
Email [parent]:	
HIN#:	

PRIORITY OF TRANSFER

- O Urgent (within 3-months)
- O Semi-urgent (within 6-months)
- O Non-urgent (within 12-months, or within 6-12 months of 18th birthday)

ALLERGIES

Medications:						



PATIENT/DISEASE CHARACTERISTICS **DEMOGRAPHICS** • Date of birth (MM/DD/YYYY): • Biologic sex (M/F/Intersex/Other): · Patient's contact information: Address: Phone: Email: **DIAGNOSIS AND PHENOTYPE** • Date of diagnosis (MM/DD/YYYY - at minimum, year of diagnosis): • Disease type (CD, UC or IBD-U): Disease location: • Phenotype (Paris or Montreal classification): **COMORBIDITIES/OTHER CHRONIC DIAGNOSES** · Related to IBD: Unrelated to IBD: THERAPEUTICS / MEDICATIONS **MEDICATIONS CURRENT AND HISTORIC** (Please list in chronological order) 1. Medication name: · Dose: • Start date (MM/DD/YYYY): Discontinuation date (MM/DD/YYYY): • Reason for stop, if applicable (e.g., side effects, complications, compliance, non-adherence): 2. Medication name: · Dose: • Start date (MM/DD/YYYY): • Discontinuation date (MM/DD/YYYY): • Reason for stop, if applicable (e.g., side effects, complications, compliance, non-adherence): 3. Medication name: · Dose:



• Start date (MM/DD/YYYY):

• Discontinuation date (MM/DD/YYYY):

• Reason for stop, if applicable (e.g., side effects, complications, compliance, non-adherence):

THERAPEUTICS / MEDICATIONS

ERAPEUTICS / MEDICATIONS	
BIOLOGICS	
(Please list in chronological order)	
Medication name:	
Dose and interval (at initial induction):	
Dose and interval (currently):	
Reasons for escalation/de-escalation:	
Recent serum titers (Refer to Labs section below):	
2. Medication name:	
Dose and interval (at initial induction):	
Dose and interval (currently):	
Reasons for escalation/de-escalation:	
Recent serum titers (Refer to Labs section below):	
3. Medication name:	
Dose and interval (at initial induction):	
Dose and interval (currently):	
Reasons for escalation/de-escalation:	
Recent serum titers (Refer to Labs section below):	
CORTICOSTEROID HISTORY	
(Please list in chronological order based on last course)	
1. Medication name:	
Number of courses:	
Last course (MM/DD/YYYY):	
Response (Dependent or Refractory):	
2. Medication name:	
Number of courses: A part source (MM/DD/XXXX):	
Last course (MM/DD/YYYY): Response (Dependent or Refractory):	
Response (Dependent of Reflactory).	
3. Medication name:	
Number of courses:	
Last course (MM/DD/YYYY):	
Response (Dependent or Refractory):	
77	



THERAPEUTICS / MEDICATIONS

SURGICAL HISTORY		
(Please list in chronological order, and include attachments for surgical and pathology reports)		
Name/description (including length of bowel resected if available):		
Date (MM/DD/YYYY):		
Pathology report [insert attachment]:		
Reason for surgery:		
Post-surgical complications (if applicable [alternative: report in Complications section below]):		
2. Name/description (including length of bowel resected if available):		
Date (MM/DD/YYYY):		
Pathology report [insert attachment]:		
Reason for surgery:		
Post-surgical complications (if applicable [alternative: report in Complications section below]):		
3. Name/description (including length of bowel resected if available):		
Date (MM/DD/YYYY):		
Pathology report [insert attachment]:		
Reason for surgery:		
Post-surgical complications (if applicable [alternative: report in Complications section below]):		



CLINICAL HISTORY AND CURRENT STATUS

	HISTORY OF PRESENTING ILLNESS
	Initial presentation at diagnosis (brief description of initial presentation and clinical course):
	Status (provide disease activity index if possible): Stable/controlled – disease activity index: Unstable/uncontrolled – disease activity index: Significant physical findings, if applicable:
_	ANTHROPOMETRICS & CURRENT STATUS
_	Weight: kg
	Patient history of growth failure: O None/non-applicable Growth failure history:
/	ESTIGATIONS
	IMAGING: ENDOSCOPIES
	(Please attach endoscopy and pathology reports)
	At diagnosis:
	Description: Date (MM/DD/YYYY):
	Disease location:
	Severity:
	Severity: Pathology report [insert attachment]:
	·
	Pathology report [insert attachment]: At last endoscopy: Description:
	Pathology report [insert attachment]: At last endoscopy: Description: Date (MM/DD/YYYY): Pathology report [insert attachment]:
	Pathology report [insert attachment]: At last endoscopy: Description: Date (MM/DD/YYYY): Disease location:
	Pathology report [insert attachment]: At last endoscopy: Description: Date (MM/DD/YYYY): Disease location: Severity:
	Pathology report [insert attachment]: At last endoscopy: Description: Date (MM/DD/YYYY): Disease location:
	Pathology report [insert attachment]: At last endoscopy: Description: Date (MM/DD/YYYY): Disease location: Severity:
	Pathology report [insert attachment]: Description: Date (MM/DD/YYYY): Disease location: Severity: Pathology report [insert attachment]: Brief listing of other endoscopies (date, results) [insert attachment if applicable]:
	Pathology report [insert attachment]: At last endoscopy: Description: Date (MM/DD/YYYY): Disease location: Severity: Pathology report [insert attachment]:



INVESTIGATIONS

ш	restigations
	IMAGING: RADIOLOGY
	Imaging results: Diagnosis/Initial Visit
	o Ultrasound results [insert attachment] o MRE results [insert attachment] o MRP results [insert attachment] o CT scan [insert attachment]
	Imaging results: Flare (most recent) O Ultrasound results [insert attachment] O MRE results [insert attachment] O MRP results [insert attachment] O CT scan [insert attachment]
	Imaging results: Most recent o Ultrasound results [insert attachment] o MRE results [insert attachment] o MRP results [insert attachment] o CT scan [insert attachment] If applicable, bone density [insert attachment]:
	mappinguise, some density [most ditacimiont].
	• Anti-saccaromyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasm antibodies (ANCA) serology:
	Measles, Mumps and Rubella (MMR) status:
	Thiopurine methyltransferase (TPMT) status:
	Viral serologies [insert attachment] o Hepatitis A o Hepatitis B o Hepatitis C o Cytomegalovirus (CMV) o Epstein-Barr Virus (EBV) o Varicella Tuberculosis testing results: IBD-related antibody serology results:
	- IDD-Telated antibody serology results.
$\overline{}$	LABS: RECENT INVESTIGATION
	 Most recent laboratory investigations Most recent serum drug titers: o Dose/interval of medication administration:



• Fecal calprotectin:

o Dose/interval of medication administration:

IISTORY OF COMPLICATIONS
HOSPITALIZATIONS
(Please attach hospital discharge summaries for notable hospitalizations)
Hospitalization #1
o Description/reason:
o Date (MM/DD/YYYY):
o Clinical course:
Hospitalization #2
o Description/reason:
o Date (MM/DD/YYYY):
o Clinical course:
OTHER COMPLICATIONS
OTHER COMPLICATIONS
IBD-related complications:
Non-IBD-related complications:
THER
FAMILY HISTORY
Relevant family history (IBD, cancer):
IMMUNIZATION HISTORY
Infectious disease history:
Missing immunizations:
Due to be given:
PSYCHOSOCIAL
NOTE: SEND SENSITIVE INFORMATION SEPARATELY OR AS AN ATTACHMENT IF PATIENT CONFIDENTIALITY MAY BE COMPROMISED
History of mental illness, substance abuse, psychosocial risk factors (sexuality/transgender challenges):



- Current and historic smoking status (including vaping):
- Current and historic cannabis use:
- Current and historic alcohol use:
- · Living situation, family conflict:
- Post-secondary details/school location:
- · Long-term life aspirations/goals:



MULTI-DISCIPLINARY TEAM

(Please provide name and contact details. Also, attach consultation reports and most recent clinical report from other specialists involved with the patient's care)

MDT involved in this patient's care:

O Surgeon:
O Rheumatologist:
O Dermatologist:
O Social Worker:
O Psychologist/Psychiatrist:

O Dietitian:
O Other type of provider:

CANIBD. Developed May 5, 2022.

Template adapted from: Benchimol EI, et al. Medical Summary Template for the Transfer of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care. J Can Assoc Gastroenterol. 2021;5(1):3-11. doi: 10.1093/jcag/gwab009.

This document was developed through CANIBD and the collaborative efforts of Frost, K, Carter, A, and Chauhan, U, with support from Amgen Canada.

